HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Turns Kratom's Future In US Dietary Supplement Market Into History

This article was originally published in The Rose Sheet

Executive Summary

FDA Commissioner Scott Gottlieb says kratom's apparently increasing use "as an alternative or adjunct to opioid use" has made enforcement on the ingredient more of a priority for FDA, and "given the scope of this crisis, we must do more."

You may also be interested in...



US Kratom Warnings Note Opioid Withdrawal Claims, Omit Unlawful Ingredient Reference

FDA and FTC joint warnings to four kratom firms as well as an essential oil marketer explain they're acting under Department of Health and Human Services’ declaration of a public health emergency involving the opioid crisis.

US Kratom Industry Chafes At FDA’s Short Leash On Science Showing Botanical’s Safety, Benefits

American Kratom Association didn’t convince court to order FDA to extend to deadline for comments responding to World Health Organization’s question on whether kratom should be deemed controlled substances under UN schedule. Short comment period is “latest in what we think is a very hostile action” by FDA about kratom, says AKA executive Mac Haddow.

FDA’s Proposed IND Study For ‘Abuse Potential’ Could Close US Kratom Supplement Market

RFP states FDA "previously warned consumers about the use of Kratom (Mitragyna speciosa)” and although botanical’s “use is prevalent, to date, clinical evaluations of abuse potential have not been performed.”

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS121319

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel